Financial Performance - SpyGlass Pharma successfully completed its Initial Public Offering (IPO) in February 2026, raising approximately $172.5 million[5]. - The company reported a net loss of $12.6 million, or ($5.72) per share, for Q4 2025, compared to a net loss of $8.4 million, or ($4.58) per share, for Q4 2024[15]. - Total assets increased to $115.866 billion as of December 31, 2025, compared to $23.318 billion in 2024[25]. - Current assets rose significantly to $108.768 billion in 2025 from $17.406 billion in 2024[25]. - Cash and cash equivalents reached $96.358 billion, a substantial increase from $16.268 billion in the previous year[25]. - Total liabilities decreased to $10.166 billion in 2025 from $11.246 billion in 2024[25]. - Total stockholders' deficit widened to $(98.837) billion in 2025 from $(60.474) billion in 2024[25]. - Common stock additional paid-in capital increased to $5.893 billion in 2025 from $4.387 billion in 2024[25]. - Accounts payable rose to $2.696 billion in 2025, up from $1.978 billion in 2024[25]. - Payroll-related accruals increased to $2.182 billion in 2025 from $1.282 billion in 2024[25]. - Other current liabilities surged to $3.706 billion in 2025 compared to $672 million in 2024[25]. - The aggregate liquidation preference for redeemable convertible preferred stock increased to $200.878 billion in 2025 from $73.542 billion in 2024[25]. Research and Development - Research and Development expenses increased to $7.7 million for Q4 2025, up from $5.7 million in Q4 2024, driven by the hiring of clinical personnel and the initiation of Phase 3 trials[12]. - The BIM-IOL System demonstrated a 34% and 42% reduction in mean intraocular pressure (IOP) for high and low dose groups, respectively, compared to a 35% reduction in the control group[4]. - 98% of evaluable patients in the 78-mcg dose group and 96% in the 39-mcg dose group were free from all topical IOP-lowering medications 12 months post-surgery[4]. - Phase 3 trials for the BIM-IOL System are ongoing, with full enrollment expected in 2027[5]. - The company anticipates presenting additional Phase 1/2 trial results at a future medical meeting[6]. - The BIM-IOL System showed a favorable safety profile with no serious ocular adverse events reported[6]. - SpyGlass Pharma plans to initiate a first-in-human trial for the Bimatoprost Drug Ring System (BIM-DRS) in the second half of 2026[20].
SpyGlass Pharma(SGP) - 2025 Q4 - Annual Results